参考文献/References:
[1] 陈孝男,杨爱琳,赵亚楠,等.缺血性脑中风的发病机制及其常用治疗中药研究进展[J].中国中药杂志,2019,44(3):422-432.
[2] 刘 寒,张欢欢,康亚国,等.黄芩苷、栀子苷配伍对脑缺血大鼠恢复期炎症因子的影响[J].陕西中医药大学学报,2018,41(3):75-81.
[3] Gao Y,Cao X,Zhang X,et al.Brozopine inhibits 15-LOX-2 metabolism pathway after transient focal cerebral ischemia in rats and OGD/R-induced hypoxia injury in PC12 cells[J].Frontiers in Pharmacology,2020,11:99.
[4] Chen Z,Yang J,Zhong J,et al.MicroRNA-193b-3p alleviates focal cerebral ischemia and reperfusion-induced injury in rats by inhibiting 5-lipoxygenase expression[J].Experimental Neurology,2020,327(5):113223.
[5] Liang G,Shi B,Luo W,et al.The protective effect of caffeic acid on global cerebral ischemia-reperfusion injury in rats[J].Behavioral and Brain Functions,2015,11(1):18.
[6] 泰文娇,叶 旋,鲍秀琦,等.小胶质细胞与脑缺血关系的研究进展[J].药学学报,2012,47(3):346-353.
[7] Kong LL,Wang ZY,Hu JF,et al.Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia[J].Neurosci Lett,2016,627:192-198.
[8] 沈 甜,张 怡,强朝阳,等.黄芩苷栀子苷配伍对脂多糖致BV2小胶质细胞激活损伤的影响[J].世界最新医学信息文摘,2017,17(45):148-150.
[9] 孟凡荣,陈 琛,万海粟,等.慢病毒载体及其研究进展[J].中国肺癌杂志,2014,17(12):870-876.
[10] 李 坤,田余祥,陈海波,等.重组人核糖核酸酶抑制因子 基因的siRNA表达载体构建及B16细胞中基因沉默的鉴定[J].应用与环境生物学报,2007,13(4):519-522.
[11] 袁晓捧,姜希娟,李悠悠,等.小胶质细胞介导的炎性反应参与脑缺血再灌注损伤的研究进展[J].中华老年心脑血管病杂志,2019,21(10):1112-1114.
[12] Murphy RC,Gijón MA.Biosynthesis and metabolism of leukotrienes[J].Biochemical Journal,2007,405(3):379-395.
[13] Yasukuni K,Wataru T,Masamichi O,et al.Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury[J].Molecular Pain,2015,11:53.
[14] 张晓燕,陈 璐,徐栋敏,等.齐留通减轻小鼠小胶质细胞介导的鱼藤酮对PC12细胞的毒性作用[J].浙江大学学报:医学版,2014,43(3):273-280.
[15] Hidekazu T,Masunari S,Masafumi I,et al.A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans[J].Acta Neuropathologica,2002,104(6):601-607.
[16] Paul R,Karli WM.Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids[J].Prostaglandins & Other Lipid Mediators,2007,83(3):188-197.
[17] Syed O,Rakesh KS,Salman H,et al.A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease[J].European Journal of Pharmacology,2019,842:208-220.
[18] Bhatt L,Roinestad K,Van T,et al.Recent advances in clinical development of leukotriene B4 pathway drugs[J].Semin Immunol,2017,33:65-73.
[19] Richards IM,Griffin RL,Ostveen JA,et al.Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs[J].Am Rev Respir Dis,1989,140(6):1712-1716.
[20] Zhang XY,Chen L,Yang Y,et al.Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1[J].Brain Research,2014,1572:59-71.
[21] Tager AM,Luster AD.BLT1 and BLT2:The leukotriene B(4)receptors[J].Prostaglandins Leukot Essent Fatty Acids,2003,69(2-3):123-134.
[22] Davino-Chiovatto JE,Oliveira-Junior MC,Mackenzie B,et al.Montelukast,leukotriene inhibitor,reduces LPS-Induced acute lung inflammation and human neutrophil activation[J].Arch Bronconeumol,2019,55(11):573-580.
[23] 王 月,刘佳俊,王 雷,等.缺血后处理通过升高血清腺苷水平减轻脑缺血再灌注损伤的实验研究[J].陕西医学杂志,2021,50(7):789-792.